vs

Side-by-side financial comparison of Community Healthcare Trust Inc (CHCT) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $30.9M, roughly 1.1× Community Healthcare Trust Inc). Community Healthcare Trust Inc runs the higher net margin — 46.6% vs -304.2%, a 350.9% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 5.6%). Community Healthcare Trust Inc produced more free cash flow last quarter ($35.9M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 2.7%).

Medical Properties Trust, Inc. (MPT) is an international real estate investment trust (REIT) based in Birmingham, Alabama that purchases and invests in healthcare facilities and for-profit healthcare holding companies, primarily in the United States and Europe. Their property acquisitions often come in the form of sale-leaseback agreements, in which the original property owner sells the property to MPT and becomes their tenant. MPT's tenants are generally subject to long-term triple net lease...

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

CHCT vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.1× larger
RXRX
$35.5M
$30.9M
CHCT
Growing faster (revenue YoY)
RXRX
RXRX
+676.1% gap
RXRX
681.7%
5.6%
CHCT
Higher net margin
CHCT
CHCT
350.9% more per $
CHCT
46.6%
-304.2%
RXRX
More free cash flow
CHCT
CHCT
$83.2M more FCF
CHCT
$35.9M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
2.7%
CHCT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CHCT
CHCT
RXRX
RXRX
Revenue
$30.9M
$35.5M
Net Profit
$14.4M
$-108.1M
Gross Margin
59.8%
Operating Margin
-304.8%
Net Margin
46.6%
-304.2%
Revenue YoY
5.6%
681.7%
Net Profit YoY
687.6%
39.6%
EPS (diluted)
$0.52
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CHCT
CHCT
RXRX
RXRX
Q4 25
$30.9M
$35.5M
Q3 25
$31.1M
$5.2M
Q2 25
$29.1M
$19.2M
Q1 25
$30.1M
$14.7M
Q4 24
$29.3M
$4.5M
Q3 24
$29.6M
$26.1M
Q2 24
$27.5M
$14.4M
Q1 24
$29.3M
$13.8M
Net Profit
CHCT
CHCT
RXRX
RXRX
Q4 25
$14.4M
$-108.1M
Q3 25
$1.6M
$-162.3M
Q2 25
$-12.6M
$-171.9M
Q1 25
$1.6M
$-202.5M
Q4 24
$1.8M
$-178.9M
Q3 24
$1.7M
$-95.8M
Q2 24
$-10.4M
$-97.5M
Q1 24
$3.7M
$-91.4M
Gross Margin
CHCT
CHCT
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
CHCT
CHCT
RXRX
RXRX
Q4 25
-304.8%
Q3 25
-3327.6%
Q2 25
-916.8%
Q1 25
-1297.9%
Q4 24
-4042.4%
Q3 24
-377.1%
Q2 24
-697.4%
Q1 24
-698.4%
Net Margin
CHCT
CHCT
RXRX
RXRX
Q4 25
46.6%
-304.2%
Q3 25
5.3%
-3135.3%
Q2 25
-43.2%
-894.2%
Q1 25
5.3%
-1373.3%
Q4 24
6.3%
-3935.5%
Q3 24
5.9%
-367.5%
Q2 24
-37.9%
-676.6%
Q1 24
12.5%
-662.4%
EPS (diluted)
CHCT
CHCT
RXRX
RXRX
Q4 25
$0.52
$-0.17
Q3 25
$0.03
$-0.36
Q2 25
$-0.50
$-0.41
Q1 25
$0.03
$-0.50
Q4 24
$0.04
$-0.56
Q3 24
$0.04
$-0.34
Q2 24
$-0.42
$-0.40
Q1 24
$0.11
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CHCT
CHCT
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$3.3M
$743.3M
Total DebtLower is stronger
$532.2M
$9.6M
Stockholders' EquityBook value
$429.4M
$1.1B
Total Assets
$990.8M
$1.5B
Debt / EquityLower = less leverage
1.24×
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CHCT
CHCT
RXRX
RXRX
Q4 25
$3.3M
$743.3M
Q3 25
$3.4M
$659.8M
Q2 25
$4.9M
$525.1M
Q1 25
$2.3M
$500.5M
Q4 24
$4.4M
$594.4M
Q3 24
$2.8M
$427.6M
Q2 24
$734.0K
$474.3M
Q1 24
$3.8M
$296.3M
Total Debt
CHCT
CHCT
RXRX
RXRX
Q4 25
$532.2M
$9.6M
Q3 25
$530.1M
$11.9M
Q2 25
$500.1M
$14.2M
Q1 25
$496.0M
$16.4M
Q4 24
$486.0M
$19.0M
Q3 24
$473.7M
$20.5M
Q2 24
$457.6M
$22.9M
Q1 24
$442.3M
Stockholders' Equity
CHCT
CHCT
RXRX
RXRX
Q4 25
$429.4M
$1.1B
Q3 25
$426.8M
$1.0B
Q2 25
$437.8M
$919.1M
Q1 25
$461.3M
$933.9M
Q4 24
$476.0M
$1.0B
Q3 24
$477.2M
$524.6M
Q2 24
$497.8M
$584.4M
Q1 24
$511.6M
$401.2M
Total Assets
CHCT
CHCT
RXRX
RXRX
Q4 25
$990.8M
$1.5B
Q3 25
$987.3M
$1.4B
Q2 25
$966.3M
$1.3B
Q1 25
$985.1M
$1.3B
Q4 24
$992.6M
$1.4B
Q3 24
$981.8M
$726.5M
Q2 24
$983.2M
$775.9M
Q1 24
$982.7M
$557.8M
Debt / Equity
CHCT
CHCT
RXRX
RXRX
Q4 25
1.24×
0.01×
Q3 25
1.24×
0.01×
Q2 25
1.14×
0.02×
Q1 25
1.08×
0.02×
Q4 24
1.02×
0.02×
Q3 24
0.99×
0.04×
Q2 24
0.92×
0.04×
Q1 24
0.86×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CHCT
CHCT
RXRX
RXRX
Operating Cash FlowLast quarter
$56.4M
$-46.1M
Free Cash FlowOCF − Capex
$35.9M
$-47.3M
FCF MarginFCF / Revenue
116.0%
-133.1%
Capex IntensityCapex / Revenue
66.3%
3.5%
Cash ConversionOCF / Net Profit
3.91×
TTM Free Cash FlowTrailing 4 quarters
$62.8M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CHCT
CHCT
RXRX
RXRX
Q4 25
$56.4M
$-46.1M
Q3 25
$12.7M
$-117.4M
Q2 25
$13.8M
$-76.4M
Q1 25
$14.4M
$-132.0M
Q4 24
$58.9M
$-115.4M
Q3 24
$13.8M
$-59.2M
Q2 24
$16.7M
$-82.2M
Q1 24
$12.6M
$-102.3M
Free Cash Flow
CHCT
CHCT
RXRX
RXRX
Q4 25
$35.9M
$-47.3M
Q3 25
$7.6M
$-117.6M
Q2 25
$9.6M
$-79.6M
Q1 25
$9.7M
$-133.8M
Q4 24
$34.2M
$-116.7M
Q3 24
$6.7M
$-63.8M
Q2 24
$9.5M
$-83.4M
Q1 24
$7.5M
$-109.0M
FCF Margin
CHCT
CHCT
RXRX
RXRX
Q4 25
116.0%
-133.1%
Q3 25
24.6%
-2272.5%
Q2 25
32.9%
-413.9%
Q1 25
32.3%
-907.4%
Q4 24
116.9%
-2567.7%
Q3 24
22.5%
-244.6%
Q2 24
34.7%
-578.5%
Q1 24
25.7%
-789.9%
Capex Intensity
CHCT
CHCT
RXRX
RXRX
Q4 25
66.3%
3.5%
Q3 25
16.3%
4.7%
Q2 25
14.5%
16.4%
Q1 25
15.6%
12.4%
Q4 24
84.1%
28.6%
Q3 24
24.2%
17.5%
Q2 24
26.1%
8.2%
Q1 24
17.4%
48.2%
Cash Conversion
CHCT
CHCT
RXRX
RXRX
Q4 25
3.91×
Q3 25
7.76×
Q2 25
Q1 25
9.06×
Q4 24
32.14×
Q3 24
7.92×
Q2 24
Q1 24
3.45×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons